Observational studyBMC cancer2025

Clinicopathological and molecular correlates of clinical benefit from disitamab vedotin (RC48), a HER-2-targeting antibody-drug conjugate, in metastatic urothelial carcinoma: a multi-center, real-world study.

Zhaopei Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.